Par Aakanksha Khajuria
New Delhi, 10 janvier (IANS): Public health experts believe that intranasal coronavirus vaccines, delivered through the nose rather than through the muscles, may be a potential game changer in India’s fight against the coronavirus pandemic.
The nasal vaccine is different from two recently approved intramuscular vaccines in that it is non-invasive, needle-free, does not require trained healthcare personnel, eliminates the risks associated with needles, is suitable for children and adults, and is manufactured scalable.
Several studies have shown that the clinical efficacy of an intranasal vaccine is greater than that of an injectable vaccine. In India, Hyderabad-based Bharat Biotech has requested approval from the Drugs Controller General of India (DCGI) to conduct clinical trials on its nasal coronavirus vaccine.
Last month, Serum Insititute of India and Pune-based Codagenix Inc announced that they had received regulatory approval in the UK to begin an early trial of their single-dose intranasal coronavirus vaccine.
“At the moment, four vaccines are in phase 1 and 2 nasal vaccine trials around the world. It can be a game-changer, but it all depends on its safety and effectiveness, ”said Lalit Kant, former head of epidemiology and infectious diseases. at the Indian Council of Medical Research (ICMR).
Referring to the benefits of the nasal vaccine, he said that its administration does not require syringes and is easy to administer, transport and store. “You can vaccinate more people in a short period of time. People would not need to come back for a second dose, ”the noted epidemiologist said.
“It’s a live attenuated vaccine. When you give it through your nose, there is the mucous membrane in the upper throat, where it is absorbed and is able to develop the antibodies. Since it penetrates directly into the mucosa, absorption is faster. Kant said.
According to Bharat Biotech, an intranasal vaccine stimulates a broad immune response at the site of infection, in the nasal lining, which is essential to block both infection and transmission of Covid-19.
“Intranasal immunization of can create an immune response in the nose, which is the entry point of the virus, thus protecting against disease, infection and transmission,” the company said in a statement.
Anish Sinha, associate professor at the Indian Institute of Public Health, said the intranasal vaccine can be a game-changer, especially in countries with logistical challenges. “Ease of administration will be the biggest advantage. It can be used in greater numbers with fewer operational challenges, ”he added.
Meanwhile, on January 3, two intramuscular vaccines – “Covaxin” from Bharat Biotech and “Covishield” from Oxford-AstraZeneca manufactured by the Serum Institute of India – were approved for restricted emergency use. These are two-dose vaccines.